466 related articles for article (PubMed ID: 9551616)
1. Recombinant E1-deleted adenovirus-mediated gene therapy for cancer: efficacy studies with p53 tumor suppressor gene and liver histology in tumor xenograft models.
Nielsen LL; Gurnani M; Syed J; Dell J; Hartman B; Cartwright M; Johnson RC
Hum Gene Ther; 1998 Mar; 9(5):681-94. PubMed ID: 9551616
[TBL] [Abstract][Full Text] [Related]
2. The use of laser scanning cytometry to assess depth of penetration of adenovirus p53 gene therapy in human xenograft biopsies.
Grace MJ; Xie L; Musco ML; Cui S; Gurnani M; DiGiacomo R; Chang A; Indelicato S; Syed J; Johnson R; Nielsen LL
Am J Pathol; 1999 Dec; 155(6):1869-78. PubMed ID: 10595917
[TBL] [Abstract][Full Text] [Related]
3. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer.
Nielsen LL; Lipari P; Dell J; Gurnani M; Hajian G
Clin Cancer Res; 1998 Apr; 4(4):835-46. PubMed ID: 9563876
[TBL] [Abstract][Full Text] [Related]
4. Adenovirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer.
Gurnani M; Lipari P; Dell J; Shi B; Nielsen LL
Cancer Chemother Pharmacol; 1999; 44(2):143-51. PubMed ID: 10412949
[TBL] [Abstract][Full Text] [Related]
5. Reduced toxicity, attenuated immunogenicity and efficient mediation of human p53 gene expression in vivo by an adenovirus vector with deleted E1-E3 and inactivated E4 by GAL4-TATA promoter replacement.
Ji L; Bouvet M; Price RE; Roth JA; Fang B
Gene Ther; 1999 Mar; 6(3):393-402. PubMed ID: 10435089
[TBL] [Abstract][Full Text] [Related]
6. Development and validation of sensitive assays to quantitate gene expression after p53 gene therapy and paclitaxel chemotherapy using in vivo dosing in tumor xenograft models.
Wen SF; Xie L; McDonald M; DiGiacomo R; Chang A; Gurnani M; Shi B; Liu S; Indelicato SR; Hutchins B; Nielsen LL
Cancer Gene Ther; 2000 Nov; 7(11):1469-80. PubMed ID: 11129289
[TBL] [Abstract][Full Text] [Related]
7. Adenovirus-mediated p53 gene therapy: overview of preclinical studies and potential clinical applications.
Horowitz J
Curr Opin Mol Ther; 1999 Aug; 1(4):500-9. PubMed ID: 11713766
[TBL] [Abstract][Full Text] [Related]
8. In vivo studies of adenovirus-mediated p53 gene therapy for cis-platinum-resistant human ovarian tumor xenografts.
Song K; Cowan KH; Sinha BK
Oncol Res; 1999; 11(3):153-9. PubMed ID: 10527075
[TBL] [Abstract][Full Text] [Related]
9. A phase I/II study of hepatic artery infusion with wtp53-CMV-Ad in metastatic malignant liver tumours.
Habib NA; Hodgson HJ; Lemoine N; Pignatelli M
Hum Gene Ther; 1999 Aug; 10(12):2019-34. PubMed ID: 10466636
[TBL] [Abstract][Full Text] [Related]
10. NK cells mediate the anti-tumor effects of E1-deleted, type 5 adenovirus in a human tumor xenograft model.
Nielsen LL
Oncol Rep; 2000; 7(1):151-5. PubMed ID: 10601610
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of p53 adenovirus-mediated gene therapy against human breast cancer xenografts.
Nielsen LL; Dell J; Maxwell E; Armstrong L; Maneval D; Catino JJ
Cancer Gene Ther; 1997; 4(2):129-38. PubMed ID: 9080122
[TBL] [Abstract][Full Text] [Related]
12. In vivo cytotoxicity of ovarian cancer cells through tumor-selective expression of the BAX gene.
Tai YT; Strobel T; Kufe D; Cannistra SA
Cancer Res; 1999 May; 59(9):2121-6. PubMed ID: 10232598
[TBL] [Abstract][Full Text] [Related]
13. Systemic IFN-beta gene therapy results in long-term survival in mice with established colorectal liver metastases.
Tada H; Maron DJ; Choi EA; Barsoum J; Lei H; Xie Q; Liu W; Ellis L; Moscioni AD; Tazelaar J; Fawell S; Qin X; Propert KJ; Davis A; Fraker DL; Wilson JM; Spitz FR
J Clin Invest; 2001 Jul; 108(1):83-95. PubMed ID: 11435460
[TBL] [Abstract][Full Text] [Related]
14. In vivo studies of adenovirus-based p53 gene therapy for ovarian cancer.
von Gruenigen VE; Santoso JT; Coleman RL; Muller CY; Miller DS; Mathis JM
Gynecol Oncol; 1998 Jun; 69(3):197-204. PubMed ID: 9648587
[TBL] [Abstract][Full Text] [Related]
15. Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma.
Mujoo K; Maneval DC; Anderson SC; Gutterman JU
Oncogene; 1996 Apr; 12(8):1617-23. PubMed ID: 8622881
[TBL] [Abstract][Full Text] [Related]
16. Advances in adenovirus-mediated p53 cancer gene therapy.
Tazawa H; Kagawa S; Fujiwara T
Expert Opin Biol Ther; 2013 Nov; 13(11):1569-83. PubMed ID: 24107178
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of multiple administrations of a recombinant adenovirus expressing wild-type p53 in an immune-competent mouse tumor model.
Li Z; Rakkar A; Katayose Y; Kim M; Shanmugam N; Srivastava S; Moul JW; McLeod DG; Cowan KH; Seth P
Gene Ther; 1998 May; 5(5):605-13. PubMed ID: 9797864
[TBL] [Abstract][Full Text] [Related]
18. Liver toxicities typically induced by first-generation adenoviral vectors can be reduced by use of E1, E2b-deleted adenoviral vectors.
Everett RS; Hodges BL; Ding EY; Xu F; Serra D; Amalfitano A
Hum Gene Ther; 2003 Dec; 14(18):1715-26. PubMed ID: 14670123
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of a replication-selective adenovirus against ovarian carcinomatosis is dependent on tumor burden, viral replication and p53 status.
Heise C; Ganly I; Kim YT; Sampson-Johannes A; Brown R; Kirn D
Gene Ther; 2000 Nov; 7(22):1925-9. PubMed ID: 11127580
[TBL] [Abstract][Full Text] [Related]
20. The role of the E1B 55 kDa gene product in oncolytic adenoviral vectors expressing herpes simplex virus-tk: assessment of antitumor efficacy and toxicity.
Wildner O; Morris JC
Cancer Res; 2000 Aug; 60(15):4167-74. PubMed ID: 10945625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
